Supernus reports Q4 EPS (7c) vs 27c last year

Reports Q4 revenue $211.6M, consensus $195.16M. “We made significant progress in 2025 against our strategic objectives, with record total revenues, including strong growth in combined revenues of our growth products, the successful acquisition of Sage Therapeutics, Inc., and the U.S. Food and Drug Administration’s approval and launch of ONAPGO for Parkinson’s disease,” said Jack Khattar, President and CEO of Supernus (SUPN). “In 2026, we are focused on continued progress of our key growth products, including resumption of new patient initiation for ONAPGO, while advancing our pipeline of promising therapeutic candidates.”